BioWorld Asia

July 11, 2007

Silence Signs AstraZeneca To $400M Respiratory Drug Deal

In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International) Read More

CureVac Receives €13M To Boost mRNA Cancer Vaccines

No Abstract Read More

One Bad SNP Carries Variant Linked To Bowel Cancer Risk

Neuropharm Gets Patients' Group Support For Autism Program

Other News To Note

GW Expands Cannabis Franchise Into CNS, Oncology Indications

EU Prediction: Europe's Biotech Future Will Depend On Change

To-BBB Raises $5.4 Million For CNS Drug Delivery

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.